Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients
- Conditions
- Liver Transplant
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 47
- Registration Number
- NCT00171743
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- Conditions
- HYPERTENSIONHYPERCHOLESTEROLEMIA
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 369
- Registration Number
- NCT00171093
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 212
- Registration Number
- NCT00171015
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 400
- Registration Number
- NCT00171184
- Locations
- 🇺🇸
Scott Department of Urology Baylor College of Medicine, Houston, Texas, United States
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 252
- Registration Number
- NCT00171171
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
🇱🇧Ali Taher, Beirut, Lebanon
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1461
- Registration Number
- NCT00171990
- Locations
- 🇦🇺
Novartis Investigative Site, North Ryde, Australia
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
- Conditions
- Glioblastoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171938
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 718
- Registration Number
- NCT00170755
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
- Conditions
- Dyspepsia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00171470
- Locations
- 🇺🇸
http://www.novartisclinicaltrials.com/etrials/DiseaseID21/Dyspepsia-clinical-trials.go, East Hanover, New Jersey, United States
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 936
- Registration Number
- NCT00171002
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland